RIGL Rigel Pharmaceuticals Inc
Price (delayed)
$18.21
Market cap
$325.28M
P/E Ratio
18.39
Dividend/share
N/A
EPS
$0.99
Enterprise value
$328.5M
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare
Highlights
The net income has surged by 170% year-on-year
Rigel Pharmaceuticals's EPS has surged by 169% YoY
The gross margin has contracted by 4.6% YoY
Key stats
What are the main financial stats of RIGL
Market
Valuations
Earnings
Shares outstanding
17.86M
Market cap
$325.28M
Enterprise value
$328.5M
Price to earnings (P/E)
18.39
Price to book (P/B)
97.56
Price to sales (P/S)
1.79
EV/EBIT
12.5
EV/EBITDA
11.52
EV/Sales
1.83
Revenue
$179.28M
Gross profit
$160.63M
Operating income
$24.19M
Net income
$17.49M
EBIT
$26.28M
EBITDA
$28.51M
Free cash flow
$31.17M
Per share
Balance sheet
Liquidity
EPS
$0.99
EPS diluted
$0.99
Free cash flow per share
$1.77
Book value per share
$0.19
Revenue per share
$10.2
TBVPS
$7.79
Total assets
$163.98M
Total liabilities
$160.69M
Debt
$59.97M
Equity
$3.29M
Working capital
$71.8M
Debt to equity
18.24
Current ratio
2.13
Quick ratio
1.88
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
15.9%
Gross margin
89.6%
Net margin
9.8%
Operating margin
13.5%
Return on assets
12.5%
Return on equity
N/A
Return on invested capital
39.2%
Return on capital employed
26.1%
Return on sales
14.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RIGL stock price
How has the Rigel Pharmaceuticals stock price performed over time
Intraday
6.18%
1 week
-4.06%
1 month
-21.03%
1 year
36.92%
YTD
8.26%
QTD
1.22%
Financial performance
How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$179.28M
Gross profit
$160.63M
Operating income
$24.19M
Net income
$17.49M
Gross margin
89.6%
Net margin
9.8%
The operating margin has soared by 177% YoY and by 125% from the previous quarter
The net income has surged by 170% year-on-year
RIGL's operating income has surged by 155% since the previous quarter
RIGL's net margin has soared by 146% YoY
Growth
What is Rigel Pharmaceuticals's growth rate over time
Valuation
What is Rigel Pharmaceuticals stock price valuation
P/E
18.39
P/B
97.56
P/S
1.79
EV/EBIT
12.5
EV/EBITDA
11.52
EV/Sales
1.83
Rigel Pharmaceuticals's EPS has surged by 169% YoY
RIGL's equity has soared by 122% from the previous quarter and by 111% YoY
Rigel Pharmaceuticals's revenue has surged by 53% YoY and by 14% QoQ
The stock's price to sales (P/S) is 42% less than its 5-year quarterly average of 2.9
Efficiency
How efficient is Rigel Pharmaceuticals business performance
Rigel Pharmaceuticals's return on sales has surged by 194% YoY and by 96% QoQ
The return on assets has surged by 159% year-on-year
RIGL's return on invested capital has surged by 124% since the previous quarter
Dividends
What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RIGL.
Financial health
How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 2% more than its total liabilities
Rigel Pharmaceuticals's total assets has increased by 40% YoY and by 18% from the previous quarter
The quick ratio has grown by 15% YoY and by 11% from the previous quarter
RIGL's equity has soared by 122% from the previous quarter and by 111% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.